HHS Grants Temporary Enforcement Discretion for Six Unapproved Peptides

Key points

• HHS announced enforcement discretion for six peptides: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500.
• Compounding pharmacies can now produce these substances without FDA approval, though they must certify purity and report side effects.
• The policy avoids a formal rule change, which would require months of public comment and scientific review.
• FDA scientists opposed the move, citing insufficient data on safety and effectiveness for these compounds.
• HHS argues the policy reduces reliance on unregulated gray-market imports from overseas.
• Critics, including former FDA officials, describe the action as a failure to enforce existing safety laws.

Background

This development follows a July advisory panel vote that narrowly supported adding these peptides to the bulk drug substances list, a process that typically takes months. The move aligns with the broader Make America Healthy Again (MAHA) agenda championed by Health Secretary Robert F. Kennedy Jr., who has publicly endorsed peptide use. Recent internal tensions within the administration, including the resignation of MAHA architect Calley Means, highlight the contentious nature of these regulatory shifts. The FDA had previously added several of these compounds to a list of substances that should not be compounded due to risks of allergic reactions and other harms.

How outlets are covering it

NBC News reports that HHS is using enforcement discretion to allow immediate access, framing it as a safety measure against black-market products. AP News highlights that FDA scientific staff strongly opposed the policy, noting that HHS shifted from seeking a formal rule to a non-enforcement approach after internal resistance. CNBC focuses on the consumer angle, noting that while some peptides like GLP-1s are approved, the unapproved variants lack robust human testing. Experts cited by CNBC and NBC, including Dr. Peter Lurie and Dr. Caleb Alexander, argue that the move prioritizes access over proven safety, potentially exposing patients to unknown risks. HHS officials, including spokesperson Emily Hilliard, maintain that the policy centers patient safety by moving users away from unregulated imports.

Why it matters

This policy shift represents a significant departure from the FDA’s traditional role in regulating drug safety. By allowing unapproved substances through enforcement discretion rather than formal approval, the government may set a precedent that weakens the regulatory framework for new drugs. For consumers, it means increased access to popular wellness products but also heightened risk from untested compounds. For the pharmaceutical industry, it could complicate the development of approved treatments by blurring the lines between regulated drugs and unverified supplements.

What to watch

The FDA is expected to continue working on a formal rule change to add these peptides to the bulk drug substances list, a process that could take several months. HHS has scheduled meetings with industry groups, including Medivant Healthcare, to discuss the implementation of the new guidelines. Public health advocates and watchdog groups are likely to monitor the safety data reported by compounding pharmacies and may push for stricter oversight or a reversal of the enforcement discretion policy if adverse effects are reported.